163 related articles for article (PubMed ID: 7602214)
21. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
Biswas S; Mondal KK
Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
[TBL] [Abstract][Full Text] [Related]
22. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
23. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
24. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low.
Gelber RH; Balagon VF; Cellona RV
Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):493-500. PubMed ID: 15755209
[TBL] [Abstract][Full Text] [Related]
25. Relapses in paucibacillary leprosy after MDT--a clinical study.
Grugni A; Nadkarni NJ; Kini MS; Mehta VR
Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):19-24. PubMed ID: 2319185
[TBL] [Abstract][Full Text] [Related]
26. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.
Fajardo TT; Villahermosa L; Pardillo FE; Abalos RM; Burgos J; Dela Cruz E; Gelber RH
Am J Trop Med Hyg; 2009 Aug; 81(2):330-4. PubMed ID: 19635893
[TBL] [Abstract][Full Text] [Related]
27. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study.
Schreuder PA
Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):149-58. PubMed ID: 9728447
[TBL] [Abstract][Full Text] [Related]
28. Relapse of leprosy after multidrug therapy.
Dasananjali K
J Med Assoc Thai; 1996 Oct; 79(10):635-9. PubMed ID: 8996998
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of MDT in multibacillary leprosy.
Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
[TBL] [Abstract][Full Text] [Related]
30. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
Pönnighaus JM; Boerrigter G
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
[TBL] [Abstract][Full Text] [Related]
31. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
[TBL] [Abstract][Full Text] [Related]
33. Hansen's disease in Portugal: multibacillary patients treated between 1988 and 2003.
Medeiros S; Catorze MG; Vieira MR
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):29-35. PubMed ID: 18713227
[TBL] [Abstract][Full Text] [Related]
34. Relapses in multibacillary leprosy patients: a retrospective cohort of 11 years in Colombia.
Guerrero-Guerrero MI; Muvdi-Arenas S; León-Franco CI
Lepr Rev; 2012 Sep; 83(3):247-60. PubMed ID: 23356026
[TBL] [Abstract][Full Text] [Related]
35. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
[TBL] [Abstract][Full Text] [Related]
36. Three years assessment of multidrug therapy in multibacillary leprosy cases.
Ganapati R; Revankar CR; Pai RR
Indian J Lepr; 1987; 59(1):44-9. PubMed ID: 3611860
[TBL] [Abstract][Full Text] [Related]
37. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
[TBL] [Abstract][Full Text] [Related]
38. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era.
Smith TC; Richardus JH
Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):353-8. PubMed ID: 7525795
[TBL] [Abstract][Full Text] [Related]
39. Fixed duration MDT in paucibacillary leprosy (classical and modified).
Nadkarni NJ; Grugni A; Kini MS
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):25-8. PubMed ID: 8326177
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcome in multibacillary (MB) leprosy patients treated with 12 months WHO MDT-MBR: a retrospective analysis of 730 patients from a leprosy clinic at a tertiary care hospital of Northern India.
Dogra S; Kumaran MS; Narang T; Radotra BD; Kumar B
Lepr Rev; 2013 Mar; 84(1):65-75. PubMed ID: 23741883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
